Literature DB >> 3005434

Serological characterization of HTLV-III infection in AIDS and related disorders.

J E Groopman, F W Chen, J A Hope, J M Andrews, R L Swift, C V Benton, J L Sullivan, P A Volberding, D P Sites, S Landesman.   

Abstract

Current efforts to test blood donors and other persons for exposure to the human T cell lymphotropic virus type III (HTLV-III), the etiologic agent of the acquired immunodeficiency syndrome (AIDS), are based on the measurement of serum antibodies to viral antigens. We studied presence of serum antibodies to HTLV-III-related antigens from 767 individuals with AIDS or AIDS-related complex (ARC) or asymptomatic persons at risk for AIDS by using ELISA and immunoblot techniques. Of the 280 specimens from AIDS and ARC subjects that were tested, 99% were ELISA reactive and 96% were immunoblot reactive. Greater than 96% of the seropositive subjects manifested antibodies to the p24 core antigen, whereas only 88% had antibodies to the gp41 envelope-related glycoprotein. Contrary to previous reports, a short incubation time in the immunoblot assay failed to detect low-titer or low-affinity antibodies that were detected by overnight incubation. There was no apparent difference in pattern of antibodies to HTLV-III-related antigens in symptomatic vs. asymptomatic seropositive individuals.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005434     DOI: 10.1093/infdis/153.4.736

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Comparison of immunoblots with neutralizing and complement fixing antibodies in experimental and natural cases of visna-maedi.

Authors:  E G Torfason; M Gudnadóttir; A Löve
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  The incidence of human immunodeficiency virus (HIV) in fetal cord samples utilized as serum supplements for in vitro fertilization.

Authors:  M D Damewood; J S Hesla; W D Schlaff; M Hubbard; J T Repke; J A Rock
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-12

4.  Densitometric analysis of Western blot (immunoblot) assays for human immunodeficiency virus antibodies and correlation with clinical status.

Authors:  G Schmidt; K Amiraian; H Frey; R W Stevens; D S Berns
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

5.  A Critical Look at HIV-Antibody Tests: 1. How Accurate Are They?

Authors:  J W Frank; V Goel; B J Harvey; R A Coates; V Schiralli
Journal:  Can Fam Physician       Date:  1987-09       Impact factor: 3.275

6.  Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection.

Authors:  R S Smith; R B Naso; J Rosen; A Whalley; Y L Hom; K Hoey; C J Kennedy; J A McCutchan; S A Spector; D D Richman
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

7.  Followup study of possible HIV seropositivity among abusers of parenteral drugs in 1971-72.

Authors:  W R Lange; J C Ball; W H Adler; E Brown; R Pyle; W Hoffman; E M Dax
Journal:  Public Health Rep       Date:  1991 Jul-Aug       Impact factor: 2.792

8.  Serological study of subjects with seroconversion to human immunodeficiency virus.

Authors:  M C Re; G Furlini; B Baldassarri; F Chiodo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

9.  Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men.

Authors:  J McCusker; A M Stoddard; K H Mayer; J Zapka; C Morrison; S P Saltzman
Journal:  Am J Public Health       Date:  1988-04       Impact factor: 9.308

10.  [Virus-specific antibody profile in various stages of HIV-1 infection. Western blot analysis of 170 patients].

Authors:  C Schulte; M Meurer; O Braun-Falco; M Held; M Fröschl
Journal:  Klin Wochenschr       Date:  1988-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.